EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Real‐World Vortioxetine Prescription for Patients With Major Depressive Disorder in Japan: A Retrospective Cohort Study Using a Japanese Health Insurance Claims Database

Masaki Kato iD, Tatsuya Hoshino iD, Yayoi Kawata iD, Fumie Tokuda iD, Shinji Fujimoto iD

Neuropsychopharmacology Reports · 2026-06 · 46 (2)

DOI: 10.1002/npr2.70133 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Neuropsychopharmacology Reports, online erschienen am 03.06.2026. Verfasst von Masaki Kato und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuropsychiatry, Faculty of Medicine, Kansai Medical University, Osaka, Japan. Hauptthemen laut MEDLINE: Antidepressive Agents, Major Depressive Disorder, Practice Patterns, Physicians', Vortioxetine. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Pharmaceutical Company Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Vortioxetine has been approved for the treatment of patients with major depressive disorder (MDD) in Japan since 2019; however, limited data are available on its use in clinical practice. This study aimed to identify real‐world prescribing patterns for first‐line antidepressant treatment of patients with MDD in Japan, and to understand how patient characteristics influence treatment selection and continuation.

Methods

This retrospective cohort study utilized data from the JMDC claims database. Patients with MDD (aged ≥ 18 years) were included if they were newly prescribed antidepressants between November 1, 2019 and May 31, 2024. The primary outcome was the distribution of antidepressants prescribed as first‐line treatment. Secondary outcomes included evaluating treatment patterns and characteristics among patients receiving a single antidepressant as first‐line therapy.

Results

The analysis population included 263 773 patients, of whom 97.4% had single‐drug prescriptions (vortioxetine [10.2%], selective serotonin reuptake inhibitors [48.3%], serotonin–norepinephrine reuptake inhibitors [15.2%], noradrenergic and specific serotonergic antidepressants [9.8%], and other antidepressants [13.9%]), and 2.6% had multiple‐drug prescriptions. Patients were less likely to be prescribed vortioxetine if they were female (odds ratio: 0.802; 95% confidence interval: 0.781–0.824) or older than 60 years (0.544; 0.498–0.594), whereas patients with somnolence (2.248; 1.152–4.385), adjustment disorders (1.488; 1.433–1.544), and nausea and vomiting (1.253; 1.194–1.315) were more likely to be prescribed vortioxetine. In the first 3 months after initiating vortioxetine treatment, 41.3% of patients continued treatment, 44.7% discontinued, and 14.0% changed treatment. Treatment change was more common in women (1.129; 1.046–1.218), and in patients with physical symptoms, whereas mental health‐related comorbidities were associated with treatment persistence.

Conclusion

These findings suggest that vortioxetine is more commonly prescribed to working‐age men in Japan, and that patient characteristics and tolerability considerations contribute to prescribing and continuation patterns in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antidepressive AgentsMajor Depressive DisorderPractice Patterns, Physicians'VortioxetineAdultAgedFemaleHumansMaleMiddle AgedCohort StudiesDatabases, FactualDrug PrescriptionsJapanRetrospective StudiesSelective Serotonin Reuptake InhibitorsEast Asian PeopleAdolescentYoung Adult

Stichwörter der Autor:innen

Japanantidepressantmajor depressive disorderprescriptionsvortioxetine

Substanzen

Antidepressive AgentsSelective Serotonin Reuptake InhibitorsVortioxetine

Autor:innen und Institutionen

  • Department of Neuropsychiatry, Faculty of Medicine, Kansai Medical University, Osaka, Japan.
  • Japan Medical Office, Takeda Pharmaceutical Co., Ltd, Tokyo, Japan.

ORCID-Profile: Masaki Kato, Tatsuya Hoshino, Yayoi Kawata, Fumie Tokuda, Shinji Fujimoto

Förderung

  • Takeda Pharmaceutical Company Ltd

Zitieren

APA

Kato, M., Hoshino, T., Kawata, Y., Tokuda, F., & Fujimoto, S. (2026). Real‐World Vortioxetine Prescription for Patients With Major Depressive Disorder in Japan: A Retrospective Cohort Study Using a Japanese Health Insurance Claims Database. Neuropsychopharmacology Reports, 46(2). https://doi.org/10.1002/npr2.70133

Vancouver

Kato M, Hoshino T, Kawata Y, Tokuda F, Fujimoto S. Real‐World Vortioxetine Prescription for Patients With Major Depressive Disorder in Japan: A Retrospective Cohort Study Using a Japanese Health Insurance Claims Database. Neuropsychopharmacology Reports. 2026;46(2). doi:10.1002/npr2.70133

BibTeX
@article{Kato2026,
  author = {Kato, Masaki and Hoshino, Tatsuya and Kawata, Yayoi and Tokuda, Fumie and Fujimoto, Shinji},
  title = {Real‐World Vortioxetine Prescription for Patients With Major Depressive Disorder in Japan: A Retrospective Cohort Study Using a Japanese Health Insurance Claims Database},
  journal = {Neuropsychopharmacology Reports},
  year = {2026},
  volume = {46},
  number = {2},
  doi = {10.1002/npr2.70133}
}
Kostenlos starten →